<DOC>
	<DOCNO>NCT01451450</DOCNO>
	<brief_summary>This study assess clinical potency several exposure level QGE031 decrease sensitivity peanut allergen .</brief_summary>
	<brief_title>Efficacy Safety 4 Doses QGE031 Patients 18-50 Years Age With Peanut Allergy</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Main Diagnosis acute peanut allergy manifest urticaria , angioedema , gastrointestinal respiratory tract symptom , acute onset symptom ingestion ( 2 hour ) . Positive peanut food challenge baseline , i.e. , objective allergic event level 300mg ( cumulative ) peanut protein placebo test . Main Prior exposure monoclonal antibody treatment Asthma patient maintenance long act betaagonists Use systemic corticosteroid Concomitant use beta blocker , ACE inhibitor , tiotropium ipratropium , antidepressant , oral betaagonists Use immunosuppressant within 6 month visit 1 Other protocoldefined inclusion/exclusion criterion may appy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Peanut Allergy</keyword>
</DOC>